Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy
Go back to Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 12.02 +0.73 (6.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.29 | 52 Week High | $2.18 | |||
| Open | $12.20 | 52 Week Low | $0.30 | |||
| Day High | $12.23 | P/E | N/A | |||
| Day Low | $11.67 | EPS | $-3.32 | |||
| Volume | 407,871 | |||||
